出版应用/物种/样本/稀释 | 参考文献 |
---|
| Massalou D, Benizri E, Chevallier A, Duranton Tanneur V, Pedeutour F, Benchimol D, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;213:377-387 pubmed 出版商
|
| Beltran H, Prandi D, Mosquera J, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298-305 pubmed 出版商
|
| Taieb J, Zaanan A, Le Malicot K, Julie C, Blons H, Mineur L, et al. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. JAMA Oncol. 2016;2:643-653 pubmed 出版商
|
| Vanoli A, Argenti F, Vinci A, La Rosa S, Viglio A, Riboni R, et al. Hepatoid carcinoma of the pancreas with lymphoid stroma: first description of the clinical, morphological, immunohistochemical, and molecular characteristics of an unusual pancreatic carcinoma. Virchows Arch. 2015;467:237-45 pubmed 出版商
|
| Vilar E, Mork M, Cuddy A, Borràs E, Bannon S, Taggart M, et al. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet. 2014;207:495-502 pubmed 出版商
|
| Dadone B, Ambrosetti D, Carpentier X, Duranton Tanneur V, Burel Vandenbos F, Amiel J, et al. A renal metanephric adenoma showing both a 2p16e24 deletion and BRAF V600E mutation: a synergistic role for a tumor suppressor gene on chromosome 2p and BRAF activation?. Cancer Genet. 2013;206:347-52 pubmed
|
| Gupte M, Tuck A, Sharma V, Williams K. Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator. PLoS ONE. 2013;8:e74071 pubmed 出版商
|
| Schroering A, Williams K. Rapid induction of chromatin-associated DNA mismatch repair proteins after MNNG treatment. DNA Repair (Amst). 2008;7:951-69 pubmed 出版商
|
| Eriksen A, Sørensen F, Lindebjerg J, Hager H, dePont Christensen R, Kjær Frifeldt S, et al. Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort. BMC Cancer. 2019;19:142 pubmed 出版商
|
| Hansen T, Kjær Frifeldt S, Eriksen A, Lindebjerg J, Jensen L, Sørensen F, et al. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. Br J Cancer. 2018;119:1367-1373 pubmed 出版商
|
| Keogh N, Chan K, Li G, Lahue R. MutS? abundance and Msh3 ATP hydrolysis activity are important drivers of CTG•CAG repeat expansions. Nucleic Acids Res. 2017;45:10068-10078 pubmed 出版商
|
| Knudsen K, Nielsen B, Lindebjerg J, Hansen T, Holst R, Sørensen F. microRNA-17 Is the Most Up-Regulated Member of the miR-17-92 Cluster during Early Colon Cancer Evolution. PLoS ONE. 2015;10:e0140503 pubmed 出版商
|
| Nakatani R, Nakamori M, Fujimura H, Mochizuki H, Takahashi M. Large expansion of CTG•CAG repeats is exacerbated by MutSβ in human cells. Sci Rep. 2015;5:11020 pubmed 出版商
|
| Bone K, Wang P, Wu F, Wu C, Li L, Bacani J, et al. NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair. Blood Cancer J. 2015;5:e311 pubmed 出版商
|
| Campregher C, Schmid G, Ferk F, Knasmuller S, Khare V, Kortüm B, et al. MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells. PLoS ONE. 2012;7:e50541 pubmed 出版商
|
| von Bueren A, Bacolod M, Hagel C, Heinimann K, Fedier A, Kordes U, et al. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. Br J Cancer. 2012;107:1399-408 pubmed 出版商
|
| Gannon A, Frizzell A, Healy E, Lahue R. MutS? and histone deacetylase complexes promote expansions of trinucleotide repeats in human cells. Nucleic Acids Res. 2012;40:10324-33 pubmed 出版商
|
| Ottenhof N, Morsink F, Ten Kate F, Van Noorden C, Offerhaus G. Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only. Cell Oncol (Dordr). 2012;35:119-26 pubmed 出版商
|